Zobrazeno 1 - 10 of 278 pro vyhledávání: '"M. Moinpour"'
1
Akademický článek
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013
Autor: Siu-Fun Wong, Joseph M. Unger, James L. Wade, Lynne I. Wagner, Mario E. Lacouture, Keisha C. Humphries, Anna Moseley, Kathryn Arnold, Mario R. Velasco, Justin D. Floyd, Benjamin T. Esparaz, Afsaneh Barzi, Heinz-Josef Lenz, Marianna Koczywas, Shaker Dakhil, Gary V. Burton, Michael J. Fisch, N. Lynn Henry, Dawn L. Hershman, Carol M. Moinpour
Publikováno v: Journal of Patient-Reported Outcomes, Vol 4, Iss 1, Pp 1-12 (2020)
Abstract Background Papulopustular rash is a common class effect of epidermal growth factor receptor inhibitors (EGFRI) that can affect patients’ health-related quality of life and cause disruptions to treatment. SWOG S1013 (NCT01416688) is a multi
Externí odkaz: https://doaj.org/article/cc8f4d5ab8574139b368be4cd9f29553
Zobrazit plný text záznamu
3
Akademický článek
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Autor: Joseph M. Unger, Katherine Griffin, Gary W. Donaldson, Karen M. Baranowski, Margorie J. Good, Eunicia Reburiano, Maha Hussain, Paul J. Monk, Peter J. Van Veldhuizen, Michael A. Carducci, Celestia S. Higano, Primo N. Lara, Catherine M. Tangen, David I. Quinn, James L. Wade, III, Nicholas J. Vogelzang, Ian M. Thompson, Jr, Carol M. Moinpour
Publikováno v: Journal of Patient-Reported Outcomes, Vol 2, Iss 1, Pp 1-10 (2018)
Abstract Background SWOG S0421 was a large randomized trial comparing docetaxel/prednisone plus placebo (DPP) to docetaxel/prednisone plus atrasentan over 12 cycles for patients with metastatic castration-resistant prostate cancer (mCRPC). The curren
Externí odkaz: https://doaj.org/article/b886bdc66c744576bec9567dfc8ec7ee
Zobrazit plný text záznamu
8
Association between body mass index and response to duloxetine for aromatase inhibitor‐associated musculoskeletal symptoms in SWOG S1202
Autor: Katherine D. Crew, Danika L. Lew, Carol M. Moinpour, James L. Wade, Cathee Till, Joseph M. Unger, Dawn L. Hershman, Anne F. Schott, Michael J. Fisch, N. Lynn Henry
Publikováno v: Cancer
BACKGROUND Aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) negatively impact adherence to and persistence with therapy. In SWOG S1202, patients with AIMSS who were treated with duloxetine, a serotonin norepinephrine reuptake inhi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b1a0af005110d8a9e1e335a2888df7
https://doi.org/10.1002/cncr.32024
Zobrazit plný text záznamu
9
Abstract P1-11-04: Association between body mass index (BMI) and response to duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS)
Autor: DL Hershman, Carol M. Moinpour, Danika Lew, Cathee Till, James L. Wade, Anne F. Schott, Norah Lynn Henry, Katherine D. Crew, Joseph M. Unger, Michael J. Fisch
Publikováno v: Cancer Research. 79:P1-11
Background: AIMSS occurs often in women treated with AI therapy for early stage breast cancer and can negatively impact adherence and persistence with therapy. Duloxetine is a serotonin norepinephrine reuptake inhibitor used to treat mood disorders a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14588347d593890c127bb37269f11a1d
https://doi.org/10.1158/1538-7445.sabcs18-p1-11-04
Zobrazit plný text záznamu
10
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202
Autor: Michael J. Fisch, Patrick J. Flynn, Anne F. Schott, Debra M. Prow, Carol M. Moinpour, Danika L. Lew, Anna Moseley, Gary V. Burton, Carl W. Sharer, Charles S. Kuzma, James L. Wade, Dawn L. Hershman, Louis Fehrenbacher, N. Lynn Henry, Joseph M. Unger
Publikováno v: Journal of Clinical Oncology. 36:326-332
Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and Drug Administration approved for treatment of multiple chronic pain disorders.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc560a353986b38d09076c84d0f320ac
https://doi.org/10.1200/jco.2017.74.6651
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje